Cyclo Therapeutics Stock Probability of Future Stock Price Finishing Over 0.14
| CYTHW Stock | USD 0.14 0.04 22.22% |
Cyclo |
Cyclo Therapeutics Target Price Odds to finish over 0.14
The tendency of Cyclo Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to move above the current price in 90 days |
| 0.14 | 90 days | 0.14 | about 57.8 |
Based on a normal probability distribution, the odds of Cyclo Therapeutics to move above the current price in 90 days from now is about 57.8 (This Cyclo Therapeutics probability density function shows the probability of Cyclo Stock to fall within a particular range of prices over 90 days) .
Assuming the 90 days horizon Cyclo Therapeutics has a beta of -2.16 suggesting as returns on its benchmark rise, returns on holding Cyclo Therapeutics are expected to decrease by similarly larger amounts. On the other hand, during market turmoils, Cyclo Therapeutics is expected to outperform its benchmark. Moreover Cyclo Therapeutics has an alpha of 1.7839, implying that it can generate a 1.78 percent excess return over Dow Jones Industrial after adjusting for the inherited market risk (beta). Cyclo Therapeutics Price Density |
| Price |
Predictive Modules for Cyclo Therapeutics
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Cyclo Therapeutics. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Cyclo Therapeutics Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. Cyclo Therapeutics is not an exception. The market had few large corrections towards the Cyclo Therapeutics' value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Cyclo Therapeutics, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Cyclo Therapeutics within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | 1.78 | |
β | Beta against Dow Jones | -2.16 | |
σ | Overall volatility | 0.05 | |
Ir | Information ratio | 0.07 |
Cyclo Therapeutics Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Cyclo Therapeutics for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Cyclo Therapeutics can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Cyclo Therapeutics is way too risky over 90 days horizon | |
| Cyclo Therapeutics has some characteristics of a very speculative penny stock | |
| Cyclo Therapeutics appears to be risky and price may revert if volatility continues | |
| Cyclo Therapeutics has accumulated 1.03 M in total debt. Cyclo Therapeutics has a current ratio of 0.85, indicating that it has a negative working capital and may not be able to pay financial obligations in time and when they become due. Note, when we think about Cyclo Therapeutics' use of debt, we should always consider it together with its cash and equity. | |
| The entity reported the revenue of 1.08 M. Net Loss for the year was (20.06 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Cyclo Therapeutics has accumulated about 2.24 M in cash with (16.19 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.32, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Cyclo Therapeutics has a frail financial position based on the latest SEC disclosures | |
| Latest headline from news.google.com: Cyclo Therapeutics, Inc. Reports Q3 Loss, Lags Revenue Estimates - MSN |
Cyclo Therapeutics Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Cyclo Stock often depends not only on the future outlook of the current and potential Cyclo Therapeutics' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Cyclo Therapeutics' indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 16.3 M | |
| Cash And Short Term Investments | 9.2 M | |
| Shares Float | 15.9 M |
Cyclo Therapeutics Technical Analysis
Cyclo Therapeutics' future price can be derived by breaking down and analyzing its technical indicators over time. Cyclo Stock technical analysis helps investors analyze different prices and returns patterns as well as diagnose historical swings to determine the real value of Cyclo Therapeutics. In general, you should focus on analyzing Cyclo Stock price patterns and their correlations with different microeconomic environments and drivers.
Cyclo Therapeutics Predictive Forecast Models
Cyclo Therapeutics' time-series forecasting models is one of many Cyclo Therapeutics' stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models are widely used for non-stationary data. Non-stationary data are called the data whose statistical properties, e.g., the mean and standard deviation, are not constant over time, but instead, these metrics vary over time. This non-stationary Cyclo Therapeutics' historical data is usually called time series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the stock market movement and maximize returns from investment trading.
Things to note about Cyclo Therapeutics
Checking the ongoing alerts about Cyclo Therapeutics for important developments is a great way to find new opportunities for your next move. Our stock alerts and notifications screener for Cyclo Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
| Cyclo Therapeutics is way too risky over 90 days horizon | |
| Cyclo Therapeutics has some characteristics of a very speculative penny stock | |
| Cyclo Therapeutics appears to be risky and price may revert if volatility continues | |
| Cyclo Therapeutics has accumulated 1.03 M in total debt. Cyclo Therapeutics has a current ratio of 0.85, indicating that it has a negative working capital and may not be able to pay financial obligations in time and when they become due. Note, when we think about Cyclo Therapeutics' use of debt, we should always consider it together with its cash and equity. | |
| The entity reported the revenue of 1.08 M. Net Loss for the year was (20.06 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Cyclo Therapeutics has accumulated about 2.24 M in cash with (16.19 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.32, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Cyclo Therapeutics has a frail financial position based on the latest SEC disclosures | |
| Latest headline from news.google.com: Cyclo Therapeutics, Inc. Reports Q3 Loss, Lags Revenue Estimates - MSN |
Additional Tools for Cyclo Stock Analysis
When running Cyclo Therapeutics' price analysis, check to measure Cyclo Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cyclo Therapeutics is operating at the current time. Most of Cyclo Therapeutics' value examination focuses on studying past and present price action to predict the probability of Cyclo Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cyclo Therapeutics' price. Additionally, you may evaluate how the addition of Cyclo Therapeutics to your portfolios can decrease your overall portfolio volatility.